Assessment templates and guidance (veterinary medicines)
Submitted by Anonymous (not verified) on 2 September 2026 - 9:10
Assessment templates and guidance (veterinary medicines)
Template - CVMP member comments on rapporteur’s reports
Submitted by Anonymous (not verified) on 2 September 2026 - 9:00
Template - CVMP member comments on rapporteur’s reports
Saxenda
Submitted by Anonymous (not verified) on 2 September 2026 - 9:00
Saxenda
Information required for early identification of a need for pre-authorisation GMP inspections
Submitted by Anonymous (not verified) on 2 September 2026 - 8:25
Information required for early identification of a need for pre-authorisation GMP inspections
Brevibloc
Submitted by Anonymous (not verified) on 2 September 2026 - 8:21
Brevibloc
Human medicines European public assessment report (EPAR): Kymriah, tisagenlecleucel, Date of authorisation: 23/08/2018, Revision: 24, Status: Authorised
Submitted by Anonymous (not verified) on 1 September 2026 - 15:45
Human medicines European public assessment report (EPAR): Kymriah, tisagenlecleucel, Date of authorisation: 23/08/2018, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): Myqorzo, aficamten, Date of authorisation: 12/02/2026, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 1 September 2026 - 15:35
Human medicines European public assessment report (EPAR): Myqorzo, aficamten, Date of authorisation: 12/02/2026, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Omvoh, mirikizumab, Date of authorisation: 26/05/2023, Revision: 9, Status: Authorised
Submitted by Anonymous (not verified) on 1 September 2026 - 15:22
Human medicines European public assessment report (EPAR): Omvoh, mirikizumab, Date of authorisation: 26/05/2023, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Seffalair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 1 September 2026 - 14:44
Human medicines European public assessment report (EPAR): Seffalair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 4, Status: Authorised
ACT EU multi-stakeholder platform annual meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, 22 October 2026
Submitted by Anonymous (not verified) on 1 September 2026 - 12:50
ACT EU multi-stakeholder platform annual meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, 22 October 2026